{
    "clinical_study": {
        "@rank": "104264", 
        "arm_group": [
            {
                "arm_group_label": "Rosuvastatin", 
                "arm_group_type": "Experimental", 
                "description": "One Rosuvastatin tablet 10mg taken once daily."
            }, 
            {
                "arm_group_label": "Crestor\u00ae", 
                "arm_group_type": "Active Comparator", 
                "description": "One Crestor\u00ae tablet 10mg taken once daily."
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of this trial is to assess the efficacy of reducing plasma low-density\n      lipoprotein(LDL) cholesterol and safety in two different brand drugs, Roty F.C. Tablets 10mg\n      and Crestor 10mg F.C. Tablets in hypercholesterolemia population."
        }, 
        "brief_title": "A Study to Evaluate the Efficacy and Safety of Rosuvastatin in Hypercholesterolemia.", 
        "condition": "Hypercholesterolemia", 
        "condition_browse": {
            "mesh_term": "Hypercholesterolemia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female aged 20 to 85;\n\n          -  LDL - C between 130 mg/dL and 250 mg/dL;\n\n          -  TG < 400 mg/dL;\n\n          -  Who without use of any statin within 2 week prior to the trial;\n\n          -  Informed consent given.\n\n        Exclusion Criteria:\n\n          -  Known hypersensitivity or history of SAE with another HMG-CoA reductase\n             inhibitor, in particular any history of myopathy;\n\n          -  Active liver disease/severe hepatic impairment(Child-Pugh C,ALT2\u00d7ULN);\n\n          -  Treatment with Cyclosporin or any disallowed drug;\n\n          -  Patients with unstable angina pectoris;\n\n          -  Pregnant, lactating women;\n\n          -  Patients who have severe medical condition(s) that in the view of the Investigator\n             prohibits participation in the trial."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01982461", 
            "org_study_id": "PSMB102ROS10-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "Rosuvastatin", 
                "description": "10mg,once daily", 
                "intervention_name": "Rosuvastatin", 
                "intervention_type": "Drug", 
                "other_name": "Roty"
            }, 
            {
                "arm_group_label": "Crestor\u00ae", 
                "description": "10mg,once daily", 
                "intervention_name": "Crestor\u00ae", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Rosuvastatin", 
                    "Crestor\u00ae"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Rosuvastatin"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 6, 2013", 
        "location": {
            "contact": {
                "email": "tsghirb@ndmctsgh.edu.tw", 
                "phone": "886-2-87923311", 
                "phone_ext": "10552"
            }, 
            "facility": {
                "address": {
                    "city": "Taipei", 
                    "country": "Taiwan", 
                    "zip": "11490"
                }, 
                "name": "Tri-Service General Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Taiwan"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Open-label, Active-controlled Study to Evaluate the Efficacy and Safety of Roty F.C. Tablets 10mg Versus Crestor 10mg F.C. Tablets in Patients With Hypercholesterolemia", 
        "overall_contact": {
            "email": "flora@twtungda.com.tw", 
            "last_name": "Lu-Hsin Lu, M.S.", 
            "phone": "886-2-26270255", 
            "phone_ext": "206"
        }, 
        "overall_official": {
            "affiliation": "Tri-Service General Hospital", 
            "last_name": "Yi-Jen Hung, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Taiwan: Department of Health", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The primary efficacy variable will be defined as the percent mean change in LDL-C from baseline to 12 weeks.", 
            "safety_issue": "No", 
            "time_frame": "baseline to week 12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01982461"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "The secondary efficacy variable will be described as the change of plasma AGE, sRAGE, Gas6 and sAx1.", 
            "safety_issue": "No", 
            "time_frame": "baseline to week 12"
        }, 
        "source": "Pin Siang Medical Biotechnology Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pin Siang Medical Biotechnology Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}